GlassScriptPhysician profile
Raphael T Bloomgarden
NPI 1700834041
$374.96
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $39.66 · 2021: $17.22.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $120.87 | 2019-2020 | |
| Amgen INC. | $102.70 | 2019 | |
| Lantheus Medical Imaging, INC. | $36.27 | 2019-2021 | |
| Irhythm Technologies, INC. | $19.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.45 | 2019 | |
| Braemar Manufacturing, LLC | $15.87 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.17 | 2019 | |
| Pfizer INC. | $12.04 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.42 | 2019 | |
| Amarin Pharma, INC. | $11.38 | 2019 | |
| Abbott Laboratories | $11.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Bloomgarden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.